Coviran vaccine safe, effective against coronavirus: Studies
Yusef Jalali
Press TV, Tehran
The second phase of the human trial for the Coviran vaccine suggests it is safe and provides effective immunity against the coronavirus.
Produced by the headquarters for the Execution of Imam Khomeini's Order, Coviran was injected to 280 volunteers in the second clinical stage and the results were reported to the Health Ministry accordingly.
Once the second phase is over and the vaccine is proved effective against the coronavirus, the third and final stage will then be initiated, which involves giving the jabs to 20,000 volunteers.
Coviran authorities say they have already issued the call for voluntary injections, since time is running short.
The first phase of the clinical trial was carried out in December last year, which proved that the vaccine is safe and will not cause any side effects.
Other than Coviran, Iran is working on seven other homegrown vaccines, including COV-PARS, which is now undergoing the first phase of the human trials.
This is as the country has already started mass vaccination, mainly using Russia's Sputnik V.
Coviran is already ahead in the race compared to other Iranian-made vaccines. Now as the fourth surge in the pandemic is sweeping the country, Coviran developers say they are doing their utmost to bring vaccine doses to the market in the next two months.
COVID 19 misinformation on Iran
Cowardly sanctions failed: Iran celebrates ‘zero’ COVID-19 deaths
Spirited Fight: Iran's latest COVID-19 map has no red, orange zones
Yemeni forces strike Israeli ship, Port of Eilat in solidarity with Gaza
Columbia, Yale students bent on ending US support for Israeli genocide
VIDEO | Genocide in Gaza
Iran calls on BRICS to play role in stopping Israeli crimes
President Raeisi’s historic visit opens new chapter in Iran-Pakistan ties
Russia: Poland’s talks on hosting US nuclear weapons ‘dangerous’
VIDEO | Israel’s genocide bounty
India’s home minister vows to end Muslim reservation if his party wins
This makes it easy to access the Press TV website
